Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286314 | 0.85 | SLC6A3 (0.76) | SLC6A3MAPTMAPK1NPSR1TP53 | |
| SCHEMBL3284872 | 0.85 | SLC6A3 (0.76) | SLC6A3MAPTMAPK1NPSR1TP53 | |
| SCHEMBL3285100 | 0.85 | SLC6A3 (0.56) | SLC6A3MAPTMAPK1NPSR1TP53 | |
| SCHEMBL3285187 | 0.85 | SLC6A3 (0.76) | SLC6A3MAPTMAPK1NPSR1TP53 | |
| Hydrochloric Acid SCHEMBL3288148 | 0.84 | SLC6A3 (0.74) | SLC6A3MAPTMAPK1NPSR1TP53 | |
| Hydrochloric Acid SCHEMBL3288153 | 0.84 | SLC6A3 (0.74) | SLC6A3MAPTMAPK1NPSR1TP53 | |
| SCHEMBL7494352 | 0.84 | SLC6A3 (0.74) | SLC6A3TP53 | |
| SCHEMBL7495913 | 0.74 | SLC6A3 (0.42) | SLC6A3TP53 | |
| SCHEMBL7494831 | 0.74 | SLC6A3 (0.42) | SLC6A3TP53 | |
| SCHEMBL6638545 | 0.74 | SLC6A3 (0.42) | SLC6A3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713956-B2 | Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-11 | — | — | US | claimed |
| EP-1745054-B1 | DEALKYLATED DERIVATIVES OF PYRROLO(2,1-B)BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2008-11-19 | — | — | EP | claimed |
| US-20070270402-A1 | Dealkylated Derivatives of Pyrrolo[2,1-B]Benzothiazepines with Atypical Antipsy-Chotic Activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-11-22 | — | — | US | claimed |
| US-7713956-B2 | Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-11 | — | — | US | disclosed |
| US-7713956-B2 | Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-11 | — | — | US | disclosed |
| EP-1745054-B1 | DEALKYLATED DERIVATIVES OF PYRROLO(2,1-B)BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2008-11-19 | — | — | EP | disclosed |
| US-20070270402-A1 | Dealkylated Derivatives of Pyrrolo[2,1-B]Benzothiazepines with Atypical Antipsy-Chotic Activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270402-A1 | Dealkylated Derivatives of Pyrrolo[2,1-B]Benzothiazepines with Atypical Antipsy-Chotic Activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| EP-1745054-A2 | DEALKYLATED DERIVATIVES OF PYRROLO(2,1-B)BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005108403-A2 | DEALKYLATED DERIVATIVES OF PYRROLO[2,1-B]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270402-A1 | Dealkylated Derivatives of Pyrrolo[2,1-B]Benzothiazepines with Atypical Antipsy-Chotic Activity | CNR1, HRH4, CNR2 | SLC6A3 405/4885MAPT 3163/4885MAPK1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.